Chemotherapeutic tumour targeting using clostridial spores

FEMS Microbiology Reviews

Volumn 17, Issue 3, 1995, Pages 357-364

  Minton, Nigel P ^a   Mauchline, Margaret L ^a   Lemmon, Marylin J ^b   Brehm, John K ^a   Fox, Mary ^b   Michael, N Paul ^a   Giaccia, Amato ^b   Brown, J Martin ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clostridium spp; Enzyme prodrug therapy; Nitroreductase; Oncolysis; Sporulation

Indexed keywords

NITROREDUCTASE; PRODRUG;

CLOSTRIDIUM; CONFERENCE PAPER; DRUG TARGETING; ENZYME ACTIVITY; MOLECULAR CLONING; NONHUMAN; SOLID TUMOR; SPOROGENESIS;

ANIMAL; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CLOSTRIDIUM; DNA, RECOMBINANT; DRUG DELIVERY SYSTEMS; MICE; NEOPLASMS; NITROREDUCTASES; PRODRUGS; SPORES, BACTERIAL; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028844617     PISSN: 01686445     EISSN: 15746976     Source Type: Journal    
DOI: 10.1016/0168-6445(95)00009-2     Document Type: Article

References (40)

1. Properties and use of botulinum toxin and other microbial neurotoxins in medicine
2. Effect of histolyticus infection and toxin on transplantable mouse tumours
3. Localisation of the vegetative form of Clostridium tetani in mouse tumours following intravenous spore administration
4. Onkolyseversuche mit apathogenen anaeroben Sporenbildern am Ehrlich-Tumour der Maus
5. Oncolysis by clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma
6. Oncolysis by clostridia. II. Experiments of a tumour spectrum with a variety of clostridia in combination with heavy metal
7. Oncolysis by clostridia. III. Effects of clostridia and chemotherapeutic agents on rodent tumours
8. Clostridial oncolysis in man
9. The liquefaction (oncolysis) of malignant gliomas by a nonpathogenic Clostridium
10. Chemotherapy for tumours using clostridial oncolysis, antibiotics and cyclophospamide: model trial on the UVT 15264 tumour
11. Treatment experiments with Clostridium butyricum-spores plus cyclophosphamide on the Jensen sarcoma of rats
12. Identification of the oncolysis by clostridia by means of radiofrequency hyperthermy in experiments on animals: dependence on dosage and intervals
13. Histamine reduction by means of oncolytically active and oncolytically non-active clostridial strains
14. Treatment experiments with glucose-induced hyperglycaemia plus Clostridium-spores on the Jensen sarcoma of rats
15. Clostridia
16. Recombinant plasmid DNA variation of Clostridium oncolyticum: model experiments of cancerostatic gene transfer
17. Antibody directed enzymes revive anti-cancer prodrug concept
18. A cytotoxic agent can be generated selectively at cancer sites
19. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds
20. Antibody-directed enzyme prodrug therapy (ADEPT): clinical report
21. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185
22. 2 gene and its expression in Escherichia coli and Pseudomonas putida
23. 2 gene
24. 2
25. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): a potent and selective inhibitor of growth of the Walker carcinoma 256
26. A new cytotoxic DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
27. The nitroreductase in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
28. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells
29. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli: a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)
30. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K-12
31. Tumour diagnosis with the Clostridium tumour test
32. Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration
33. Electro-transformation of Clostridium beijerinckii NRRL B-592 with shuttle plasmid pHR106 and recombinant derivatives
34. Origins and relationships of industrial solvent producing clostridial strains
35. Phenotypic and genotypic differences between certain strains of Clostridium acetobutylicum
36. Anaerobic bacteria as a gene delivery system to tumours
37. Clostridial cloning vectors
38. Isolation and partial characterisation of three cryptic plasmids from strains of Clostridium butyricum